BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Etemadifar M, Abhari AP, Nouri H, Sigari AA, Piran Daliyeh SM, Maracy MR, Salari M, Maleki S, Sedaghat N. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Hum Vaccin Immunother 2022;18:2041945. [PMID: 35201963 DOI: 10.1080/21645515.2022.2041945] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Etemadifar M, Nouri H, Salari M, Sedaghat N. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Hum Vaccin Immunother 2022;18:2033540. [PMID: 35239452 DOI: 10.1080/21645515.2022.2033540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wang C, Chen LY, Lu QB, Cui F. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease. Vaccines (Basel) 2022;10:920. [PMID: 35746530 DOI: 10.3390/vaccines10060920] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]